<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238679</url>
  </required_header>
  <id_info>
    <org_study_id>B1701002</org_study_id>
    <nct_id>NCT01238679</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Subject and Investigator-Blind, Sponsor Open, Multiple Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study evaluates the safety and tolerability of multiple,
      escalating doses of PF-04958242 administered orally to healthy adult participants.This study
      also evaluates the plasma and urine multiple dose pharmacokinetics (PK) of PF-04958242.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A decision was made to terminate the B1701002 study so that emerging data from the study and
      from a preclinical study in rats could be further examined and incorporated into a new study
      design and protocol.

      This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to
      Biogen.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.
  </why_stopped>
  <start_date type="Actual">November 24, 2010</start_date>
  <completion_date type="Actual">May 3, 2011</completion_date>
  <primary_completion_date type="Actual">May 3, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Adverse Events and Serious Adverse Events</measure>
    <time_frame>Baseline up to Day 23</time_frame>
    <description>An adverse event is any untoward medical occurrence in a clinical investigation subject administered a product or medical device. A serious adverse event or serious adverse drug reaction is any untoward medical occurrence at any dose that: Results in death; Is life-threatening (immediate risk of death); Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent or significant disability/incapacity; Results in congenital anomaly/birth defect.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Drug Concentration (Cmax) for Single Dose</measure>
    <time_frame>Day 1 and at multiple time points up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) for Single Dose</measure>
    <time_frame>Day 1 and at multiple time points up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Time-curve During a Dosage Interval (AUCτ) for Single Dose</measure>
    <time_frame>Day 1 and at multiple time points up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for Steady State</measure>
    <time_frame>Day 1 and at multiple time points up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Drug Concentration-Time Curve During a Dosage Interval (AUCτ) for Steady State</measure>
    <time_frame>Day 1 and at multiple time points up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Clearance of the Drug from Plasma (CL/F) for Steady State</measure>
    <time_frame>Day 1 and at multiple time points up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution During Terminal Phase (Vz/F) for Steady State</measure>
    <time_frame>Day 1 and at multiple time points up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Half-Life (t1/2) for Steady State</measure>
    <time_frame>Day 1 and at multiple time points up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio (AUC(τ,ss)/AUC(τ,sd)) for Steady State</measure>
    <time_frame>Day 1 and at multiple time points up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Dose Eliminated in Urine Unchanged (Ae%)</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of PF-04958242 Eliminated in Urine Unchanged (Ae)</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLr)</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) for Steady State</measure>
    <time_frame>Day 1 and at multiple time points up to Day 17</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an oral solution of 0.03 milligrams (mg) of PF-04958242, every 12 hours for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an oral solution of 0.05 mg of PF-04958242, every 24 hours for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an oral solution of 0.10 mg of PF-04958242, every 24 hours for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an oral solution of 0.15 mg of PF-04958242, every 24 hours for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an oral solution of 0.20 mg of PF-04958242, every 24 hours for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an oral solution of 0.25 mg of PF-04958242, every 24 hours for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received an oral solution of matching placebo, every 12 or 24 hours for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04958242</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Body Mass Index (BMI) of 17.5 to 30.5 kilograms per meter quared (kg/m2);

          -  Total body weight &gt;50 kilograms (kg) (110 pounds [lbs]);

        Key Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing);

          -  Positive urine drug screen;

          -  Pregnant or nursing females, and females of child bearing potential;

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality
             that may increase the risk associated with study participation or investigational
             product administration or may interfere with the interpretation of study results and,
             in the judgment of the investigator, would make the participant inappropriate for
             entry into this study.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singapore</city>
        <zip>188770</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2010</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

